Proteomics International Laboratories Ltd. (AU:PIQ)
ASX:PIQ
PIQ Stock Chart & Stats
AU$0.67
AU$0.03(4.23%)
At close: 4:00 PM EST
AU$0.67
AU$0.03(4.23%)
Day’s Range― - ―
52-Week RangeAU$0.23 - AU$0.86
Previous CloseN/A
Volume90.30K
Average Volume (3M)426.90K
Market Cap
AU$37.99M
Enterprise ValueAU$31.00M
Total Cash (Recent Filing)AU$7.67M
Total Debt (Recent Filing)AU$681.45K
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding165,184,000
10 Day Avg. Volume295,611
30 Day Avg. Volume426,904
Financial Highlights & Ratios
PEG Ratio-0.84
Price to Book (P/B)3.69
Price to Sales (P/S)50.61
P/FCF Ratio-7.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.43Price Target Upside-35.82% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)AU$4.30M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Capital StructureVery low debt-to-equity provides durable financial flexibility over the medium term. With minimal fixed financing costs, the company faces lower insolvency risk and can better allocate limited cash toward R&D, regulatory work or scaling lab capacity without immediate refinancing pressure.
Diversified Revenue Model (diagnostics + Services)Having both diagnostic product/testing revenue and fee-for-service laboratory work creates two structural revenue levers. Contract proteomics fees can provide recurring, project-driven cash inflows that partially offset diagnostic commercialisation cyclicality and support longer-term commercial scaling.
Economics: Positive Gross Margin On Core ActivitiesA positive gross margin shows core laboratory tests and proteomics services can be economically viable at unit level. If volumes grow and operating expenses are controlled, gross-margin strength supports a path to sustainable profitability as scale dilutes fixed costs and improves operating leverage.
Bears Say
Sharp Revenue DeclineA very large revenue drop is a structural red flag: it erodes scale economics, weakens pricing power, and prolongs the time to profitability. Persistent declines reduce utilization of lab capacity and make fixed cost absorption harder, undermining medium-term recovery prospects.
Negative Operating And Free Cash FlowSustained negative operating and free cash flow create runway risk and constrain strategic options. Over several months, continued cash burn forces capital raises or severe cost cuts, which can dilute shareholders, disrupt growth initiatives or delay commercialization investments.
Ongoing Operating Losses And Weak ProfitabilityConsistent operating losses and negative margins indicate structural expense pressure relative to current revenue. Without sustained revenue recovery or structural cost reductions, losses will persist, limiting the company’s ability to reinvest in commercialisation or R&D and delaying attainment of sustainable profitability.
Proteomics International Laboratories Ltd. News
PIQ FAQ
What was Proteomics International Laboratories Ltd.’s price range in the past 12 months?
Proteomics International Laboratories Ltd. lowest share price was AU$0.23 and its highest was AU$0.86 in the past 12 months.
What is Proteomics International Laboratories Ltd.’s market cap?
Proteomics International Laboratories Ltd.’s market cap is AU$37.99M.
When is Proteomics International Laboratories Ltd.’s upcoming earnings report date?
Proteomics International Laboratories Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 148 days.
How were Proteomics International Laboratories Ltd.’s earnings last quarter?
Proteomics International Laboratories Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.04 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.04.
Is Proteomics International Laboratories Ltd. overvalued?
According to Wall Street analysts Proteomics International Laboratories Ltd.’s price is currently Overvalued.
Does Proteomics International Laboratories Ltd. pay dividends?
Proteomics International Laboratories Ltd. does not currently pay dividends.
What is Proteomics International Laboratories Ltd.’s EPS estimate?
Proteomics International Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteomics International Laboratories Ltd. have?
Proteomics International Laboratories Ltd. has 165,184,000 shares outstanding.
What happened to Proteomics International Laboratories Ltd.’s price movement after its last earnings report?
Proteomics International Laboratories Ltd. reported an EPS of -AU$0.04 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.817%.
Which hedge fund is a major shareholder of Proteomics International Laboratories Ltd.?
Currently, no hedge funds are holding shares in AU:PIQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Proteomics International Laboratories Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
AU$0.43 (-35.82% Downside)
AU$0.43 (-35.82% Downside)
Blogger Sentiment
Bullish
AU:PIQ Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.16%
12-Months-Change
Fundamentals
Return on Equity
-93.66%
Trailing 12-Months
Asset Growth
60.94%
Trailing 12-Months
Company Description
Proteomics International Laboratories Ltd.
Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute and the Janssen Research & Development for the research of diabetic kidney disease treatment; and partnership with QIMR Berghofer Medical Research Institute for the detection of oesophageal adenocarcinoma. The company was founded in 2001 and is based in Perth, Australia.
PIQ Stock 12 Month Forecast
Average Price Target
AU$0.43
▼(-35.82% Downside)
Technical Analysis
Prescient Therapeutics Limited
―
Pharmaust Limited
―
Chimeric Therapeutics Ltd.
―
Radiopharm Theranostics Limited
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---